Avecho Biotechnology 관리

관리 기준 확인 4/4

Avecho Biotechnology CEO는 Paul Gavin, May2020 에 임명되었습니다 의 임기는 4.5 년입니다. 총 연간 보상은 A$ 291.80K, 77.8% 로 구성됩니다. 77.8% 급여 및 22.2% 보너스(회사 주식 및 옵션 포함). 는 A$ 21.72K 가치에 해당하는 회사 주식의 0.34% 직접 소유합니다. 21.72K. 경영진과 이사회의 평균 재임 기간은 각각 4.5 년과 7.2 년입니다.

주요 정보

Paul Gavin

최고 경영자

AU$291.8k

총 보상

CEO 급여 비율	77.8%
CEO 임기	4.5yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	7.2yrs

최근 관리 업데이트

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13

CEO 보상 분석

Paul Gavin 의 보수는 Avecho Biotechnology 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-AU$3m
Mar 31 2024	n/a	n/a	-AU$3m
Dec 31 2023	AU$292k	AU$227k	-AU$3m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	n/a	n/a	-AU$4m
Mar 31 2023	n/a	n/a	-AU$3m
Dec 31 2022	AU$355k	AU$227k	-AU$2m
Sep 30 2022	n/a	n/a	-AU$2m
Jun 30 2022	n/a	n/a	-AU$2m
Mar 31 2022	n/a	n/a	-AU$3m
Dec 31 2021	AU$477k	AU$227k	-AU$3m
Sep 30 2021	n/a	n/a	-AU$3m
Jun 30 2021	n/a	n/a	-AU$3m
Mar 31 2021	n/a	n/a	-AU$3m
Dec 31 2020	AU$497k	AU$231k	-AU$3m
Sep 30 2020	n/a	n/a	-AU$2m
Jun 30 2020	n/a	n/a	-AU$2m
Mar 31 2020	n/a	n/a	-AU$739k
Dec 31 2019	AU$235k	AU$200k	AU$850k
Sep 30 2019	n/a	n/a	AU$504k
Jun 30 2019	n/a	n/a	AU$158k
Mar 31 2019	n/a	n/a	-AU$2m
Dec 31 2018	AU$231k	AU$200k	-AU$4m
Jun 30 2018	n/a	n/a	-AU$6m
Mar 31 2018	n/a	n/a	-AU$7m
Dec 31 2017	AU$238k	AU$200k	-AU$9m

보상 대 시장: Paul 의 총 보상 ($USD 190.07K ) Australian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 298.55K ).

보상과 수익: Paul 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Paul Gavin

4.5yrs

테뉴어

AU$291,796

보상

Dr. Paul Gavin, BSc (Hons), PhD serves as Chief Executive Officer of Avecho Biotechnology Limited (formerly known as Phosphagenics Limited) since May 01, 2020 and served as its Chief Scientific Officer unt...

리더십 팀

이름	위치	테뉴어	보상	소유권
Paul Gavin	Chief Executive Officer	4.5yrs	AU$291.80k	0.34% A$ 21.7k
Roksan Libinaki	Chief Operating Officer	4.5yrs	AU$242.70k	0.35% A$ 22.2k
Melanie Leydin	Company Secretary & CFO	5.9yrs	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

경험이 풍부한 관리: AVE 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ross Murdoch	Independent Director	9.6yrs	AU$65.32k	0.11% A$ 6.7k
Gregory Collier	Independent Non-Executive Chairman	9.6yrs	AU$115.10k	0.37% A$ 23.3k
Simon West	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Matthew McNamara	Independent Non-Executive Director	4.8yrs	AU$65.32k	0.053% A$ 3.3k
Katherine Connell	Non-Executive Director	less than a year	데이터 없음	데이터 없음

7.2yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: AVE 의 이사회는 경험(평균 재직 기간 7.2 년)으로 간주됩니다.

Avecho Biotechnology 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First half 2024 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2023)

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in FY 2021)

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Athenex Submits Avecho's Phytonadione to FDA Pre-IND

Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia

Less than half of directors are independent

Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk

First half 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2021)

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Less than half of directors are independent

Avecho Biotechnology Limited Announces Positive Results for Its Phase IIa Study

Avecho Biotechnology Limited Announces Dosing Commencement for CBD Topical Osteoarthritis Study in collaboration with the Lambert Initiative

Full year 2021 earnings: Revenues miss analyst expectations

Avecho Biotechnology Limited Releases Results for Its Australian Phase I PK Study Characterizing the Absorption Profile of Cannabidiol from Avecho's Proprietary CBD Soft-Gel Product

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD Absorption

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Non-Independent Non-Executive Director David Segal has left the company

Avecho Biotechnology Limited Completes Pharmaceutical CBD Soft-Gel Product

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

Avecho Biotechnology Begins Human Trial on CBD Product

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Avecho Biotechnology Limited Provides TPM Cannabinoid Development Program Update

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령